1. Follicular and endocrine profiles associated with different GnRH-antagonist regimens: a randomized controlled trial 
Juan Antonio García-Velasco, Sanja Kupesic, Antonio Pellicer, Claire Bourgain, Carlos Simón, Milan Mrazek, Paul Devroey, Joan-Carles Arce 
Reproductive BioMedicine Online 
Volume 24, Issue 2, Pages (February 2012)
DOI: /j.rbmo
Copyright © 2011 Reproductive Healthcare Ltd. Terms and Conditions

2. Figure 1
Overview of the gonadotrophin-releasing hormone (GnRH) antagonist treatment regimens for oocyte donors. (A) Degarelix starting in the mid-luteal phase. (B) Degarelix starting in the early follicular phase. (C) Ganirelix starting in the mid-follicular phase. HCG=human chorionic gonadotrophin; HP-HMG=highly purified human menopausal gonadotrophin; OR=oocyte retrieval; P4=progesterone.
Reproductive BioMedicine Online  , DOI: ( /j.rbmo )
Copyright © 2011 Reproductive Healthcare Ltd. Terms and Conditions

3. Figure 2
Study flow chart of the oocyte donors. GnRH=gonadotrophin-releasing hormone; ITT=intention to treat.
Reproductive BioMedicine Online  , DOI: ( /j.rbmo )
Copyright © 2011 Reproductive Healthcare Ltd. Terms and Conditions

4. Figure 3
Individual coefficients of variation of follicular size at screening on day 3±1 of the natural cycle and on stimulation day 1 in oocyte donors treated with placebo (n=39) (A) or GnRH antagonist (n=39) (B) in the mid-luteal phase of the natural cycle (the degarelix-ML group). The horizontal dashed line displays the 75th percentile (47.1%) of the whole trial population at screening.
Reproductive BioMedicine Online  , DOI: ( /j.rbmo )
Copyright © 2011 Reproductive Healthcare Ltd. Terms and Conditions